Biosimilars Market is expected to Hit US$ 99.3 Billion by 2033 | Major Companies - Pfizer, Inc., Amgen Inc., Celltrion, Inc., Biocon Limited, Viatris Inc.

DataM Intelligence has unveiled its latest report on the "Biosimilars Market Size 2026" delivering powerful insights into key trends, future growth opportunities, and evolving market challenges. Designed to empower smarter decision-making, the report equips businesses with the strategic intelligence needed to stay ahead in a competitive landscape. By blending robust qualitative analysis with data-driven quantitative research, DataM Intelligence offers a well-rounded perspective that helps organizations decode complex market dynamics, unlock new avenues for growth, and seize emerging opportunities in an ever-evolving global market.

Unlock Strategic Partnerships in the Growing Biosimilars Market-Connect with Key Industry Leaders Today: https://www.datamintelligence.com/partner-identification-enquiry/biosimilars-market?sz

The Global Biosimilars Market size reached US$ 30.30 Billion in 2024, rising to US$ 34.57 Billion in 2025 and is expected to reach US$ 99.3 Billion by 2033, growing at a CAGR of 14.1% from 2026 to 2033.

The Biosimilars Market refers to the segment of the biopharmaceutical industry focused on developing, manufacturing, and commercializing biosimilar products, which are highly similar versions of approved biologic drugs with no clinically meaningful differences in safety, purity, or efficacy. These products are introduced after patent expiration of original biologics to improve patient access and reduce treatment costs. The market is driven by rising chronic disease prevalence, healthcare cost pressures, regulatory support, and increasing acceptance of biologic therapies across global healthcare systems and providers.

Download Free Sample Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/biosimilars-market?sz

Recent Industry Developments: United States

✅ April 2026: The U.S. biosimilars market reported continued acceleration in approvals and commercialization momentum, with total FDA-approved biosimilars reaching ~92 products across multiple therapeutic classes. Regulatory flexibility in evidence requirements is improving development speed and lowering entry barriers for manufacturers.

✅ March 2026: The FDA introduced updated draft regulatory guidance allowing greater flexibility in biosimilar development, including reduced requirements for comparative clinical efficacy studies and acceptance of external clinical data, significantly cutting development cost and timelines.

✅ January 2026: U.S. biosimilar expansion continued with multiple new approvals and pipeline strengthening, including oncology and immunology biosimilars. The market also saw increasing adoption of alternative reimbursement and PBM models aimed at improving biosimilar uptake and price competition.

Recent Industry Developments: Japan

✅ May 2026: Japan advanced biosimilar commercialization through staged market entry agreements, including new biologic biosimilars (such as aflibercept-based therapies) scheduled for phased launches beginning May 2026 across ophthalmology indications.

✅ April 2026: Japan expanded its biosimilar and biologics framework with new regulatory approvals in autoimmune therapies, including antibody-based biosimilars such as ustekinumab, reflecting stronger acceptance of biosimilars in specialty care segments.

✅ February 2026: Japan strengthened its biotechnology and biopharmaceutical strategy through new government-led working groups focusing on biopharma innovation, biosimilars supply chain resilience, and accelerated approval pathways to enhance domestic biologics competitiveness.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/biosimilars-market?sz

List of the Key Players in the Biosimilars Market:

Pfizer, Inc.
Amgen Inc.
Novartis AG (Sandoz division)
Samsung Bioepis Co., Ltd.
Celltrion, Inc.
Biocon Limited
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim International GmbH
Merck KGaA
F. Hoffmann-La Roche Ltd.
Dr. Reddy's Laboratories Ltd.
STADA Arzneimittel AG
Fresenius Kabi AG
Apotex Inc.

How Does Market Research Work in the Biosimilars Market?

Market research for the Biosimilars Market involves systematic data collection and analysis to understand industry trends, customer behavior, and competitive dynamics. It includes primary research such as surveys and interviews, and secondary research from reports, databases, and publications. Analysts evaluate market size, growth drivers, challenges, and opportunities using qualitative and quantitative methods. Insights are validated through expert opinions and forecasting models, enabling businesses to make strategic decisions, identify target segments, and gain a competitive advantage in a rapidly evolving market.

Latest Mergers and Acquisitions of Biosimilars Market:

✅ April 2026: Amneal Pharmaceuticals → Kashiv BioSciences Acquisition
➠ Amneal Pharmaceuticals agreed to acquire Kashiv BioSciences in a deal valued at up to $1.1 billion, strengthening its biosimilars pipeline and manufacturing capabilities. The acquisition includes Kashiv's biosimilar assets and late-stage oncology and immunology programs, aiming to build a fully integrated biosimilars platform in the U.S.
➠ Key Biosimilar Relevance:
Includes pegfilgrastim biosimilar (Fylnetra)
Expands pipeline in oncology and autoimmune therapies
Strengthens U.S. biosimilar commercialization scale

✅ April 2026: Sun Pharmaceutical Industries → Organon Acquisition
➠ Sun Pharma signed a definitive agreement to acquire Organon & Co. in an all-cash deal worth $11.75 billion, marking one of the largest pharma acquisitions of 2026. The deal significantly expands Sun's biosimilars footprint along with women's health and specialty medicines.
➠ Key Biosimilar Relevance:
Adds established biosimilar products (e.g., immunology portfolio assets)
Strengthens global biosimilar commercialization reach
Positions Sun Pharma among top global biosimilar players

✅ January 2026: BioCryst Pharmaceuticals → Astria Therapeutics Acquisition
➠ BioCryst completed its acquisition of Astria Therapeutics, enhancing its leadership in rare disease biologics and biosimilar-adjacent biologic therapies. The deal adds navenibart, a long-acting injectable biologic targeting hereditary angioedema (HAE).
➠ Key Biosimilar Relevance:
Expands biologics pipeline in rare disease space
Strengthens long-acting injectable therapeutic portfolio
Supports combination biologics strategy in specialty care

Segments Covered in the Biosimilars Market 2026:

By Drug Class: Monoclonal Antibodies, Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors, Granulocyte Colony-Stimulating Factor (G-CSF), Insulin, Erythropoietin, Human Growth Hormone, Follitropin, Interferons, Anti-Vascular Endothelial Growth Factor, Other Drug Classes.

By Therapeutic Area: Oncology, Immunology & Autoimmune Diseases, Metabolic Diseases (including diabetes), Neurology, Infectious Diseases, Rare Diseases, Others.

By Manufacturing Modality: Mammalian Cell-Based Biosimilars, Microbial-Based Manufacturing, Plasma-Derived Manufacturing, and Other Manufacturing Platforms.

By Route of Administration: Intravenous, Subcutaneous, Intramuscular, Others.

By End-User: Hospitals & Specialty Clinics, Infusion Centers, Specialty Pharmacies, Others.

Regional Analysis of the Biosimilars Market:

⇥ North America: Leads the market due to advanced infrastructure, strong R&D investments, and early adoption of new technologies.

⇥ Europe: Shows steady growth supported by strict regulations and increasing focus on sustainability initiatives.

⇥ Asia-Pacific: Fastest-growing region driven by rapid industrialization, urbanization, and rising consumer demand in emerging economies.

⇥ Latin America: Experiences moderate growth with expansion in industrial and commercial sectors.

⇥ Middle East & Africa: Gradual market growth supported by increasing investments and improving economic conditions.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=biosimilars-market

Key Benefits of the Report:

⏩ Comprehensive Market Insights: Gain a deep understanding of market size, trends, and structure.

⏩ Accurate Forecasting: Access reliable future projections to support long-term planning.

⏩ Competitive Analysis: Identify key players, strategies, and positioning in the market.

⏩ Data-Driven Decisions: Make informed business choices backed by verified data.

⏩ Opportunity Identification: Discover emerging trends and untapped growth areas.

⏩ Risk Mitigation: Reduce uncertainties with thorough market evaluation.

⏩ Customer Insights: Understand consumer behavior, preferences, and buying patterns.

⏩ Strategic Planning Support: Align business strategies with market realities.

⏩ Time & Cost Efficiency: Save resources by leveraging ready-to-use research.

⏩ Customization & Expert Validation: Benefit from tailored insights and industry expert analysis.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Biosimilars Market in 2025?
◆ What is the projected growth rate of the Biosimilars Market through 2033?
◆ Who are the key players in the Biosimilars Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Fabian
Email: fabian@datamintelligence.com
Phone USA: +1 877-441-4866
Phone UK: +44 161-870-5507
Website:https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.